![](https://immunomart.com/wp-content/uploads/2024/03/HY-110033.gif)
Download Files:
Ecopipam (hydrobromide)
SKU
HY-110033-1 mg
Category Reference compound
Tags 5-HT Receptor;Adrenergic Receptor;Dopamine Receptor, GPCR/G Protein;Neuronal Signaling, Metabolic Disease; Neurological Disease
$450
Only 1000 item(s) left in stock.
Products Details
Product Description
– Ecopipam (SCH 39166) hydrobromide is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrobromide shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam hydrobromide can be used for the research of schizophrenia and obesity[1].
Web ID
– HY-110033
Storage Temperature
– -20°C (Powder, sealed storage, away from moisture)
Shipping
– Blue Ice
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C19H21BrClNO
References
– [1]Wu WL, et al. Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. J Med Chem. 2005 Feb 10;48(3):680-93.|[2]Sharopov S, et al. Dopaminergic modulation of low-Mg²⁺-induced epileptiform activity in the intact hippocampus of the newborn mouse in vitro. J Neurosci Res. 2012 Oct;90(10):2020-33.|[3]Satanove DJ, et al. Nicotine-induced enhancement of a sensory reinforcer in adult rats: antagonist pretreatment effects. Psychopharmacology (Berl). 2021 Feb;238(2):475-486.|[4]R E Chipkin, et al. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther. 1988 Dec;247(3):1093-102. |[5]E Acquas, et al. Local application of SCH 39166 reversibly and dose-dependently decreases acetylcholine release in the rat striatum. Eur J Pharmacol. 1999 Nov 3;383(3):275-9.
CAS Number
– 2587360-22-1
Molecular Weight
– 394.73
Compound Purity
– 99.0
SMILES
– CN1[C@]2([H])[C@@](C3=CC=CC=C3CC2)([H])C4=CC(O)=C(Cl)C=C4CC1.Br
Clinical Information
– Phase 3
Research Area
– Metabolic Disease; Neurological Disease
Solubility
– 10 mM in DMSO
Target
– 5-HT Receptor;Adrenergic Receptor;Dopamine Receptor
Isoform
– 5-HT Receptor;D1 Receptor;D2 Receptor;D4 Receptor;D5 Receptor;α adrenergic receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.